ACP-196
-
- Catalog#: C-1016
- Targets: BTK
- Synonym: ACP-196, ACP196, ACP 196, Acalabrutinib
Technical Data
- Product Name: ACP-196
- Chemical Formula: n/a
- Moleculer Weight: 244.29
- CAS#: 1420477-60-6
- Appearance: Solid powder
- Purity: > 99% by HPLC
- Solubility: Soluble in DMSO
- Storage: Room temperature for months, or -20ºC for 3 years
Description
ACP-196 (Acalabrutinib) is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, leading to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies. It plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.